It remains an open question, whether one or another from the growing list of different therapeutic drugs that have shown to reduce viral infection of human bronchial epithelial cells and their consequences in vitro, to which PDE4 inhibitors are now added, may translate into a favorable outcome in controlled clinical trials. Here, PDE4A is linked to viral infectious disease.